Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

About this update from Pfizer, Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios ","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Year end 2025 Cash of $751 million ","length":34,"tagName":"p"}]},{"val":[{"type":"text","content":"Novavax exceeded its full year 2025 R&D and SG&A expense reduction goals and is improving future targets ","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":772,"olType":false},{"type":"text","content":"GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.","length":199,"tagName":"p"},{"type":"text","content":""In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M® adjuvant technology and the advancement of our own R&D efforts," said John C. Jacobs, President and Chief Executive Officer, Novavax. "With a strong start to 2026, including the recently announced Pfizer Matrix-M agreement, we look forward to commercial and clinical development execution from our partners, advancing our R&D efforts and the potential for more partnerships as we drive vaccine innovation and value creation from our technology."","length":768,"tagName"...

More updates from Pfizer, Inc.